Back to results
US 2022/0175922 A1Published application
Antibody formulation
AssigneeGlaxoSmithKline Intellectual Property Management Limited
InventorsAngela BLAKE-HASKINS, Tristan MARSHALL, Melissa D. PERKINS, Kristin O'BERRY
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.
Claims10
A pharmaceutical formulation for an antigen binding protein comprising:
- a. about 150 to 250 mg/mL of the antigen binding protein;
- b. about 1 to 100 mM of a buffering agent providing a pH of about 5.0 to about 7.0;
- and
- c. about 70 to 170 mM of a tonicity agent,
- wherein the antigen binding protein is a monoclonal antibody or fragment thereof and binds to BLyS (SEQ ID NO:
- 1) or a hetero- or homo-trimeric form of BLyS, and
- wherein the pharmaceutical formulation is suitable for subcutaneous administration.
4 more elements
Dependencies are inferred from the claim text.